EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection

Inderjit Mehmi, Jonathan E Cohen, Kathryn Bollin, Siwen Hu-Lieskovan, Adam Dugan, Binyam Yilma, Stamatina Fragkogianni, Unnati Jariwala, Jacob Mercer, Omid Hamid

The Oncologist · 2026-11-12

DOI: 10.1093/oncolo/oyag441 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Multiple first-line immune checkpoint regimens are approved for advanced melanoma, yet no biomarker reliably guides their selection. LAG-3, an inhibitory checkpoint enriched on exhausted immune cells, may reflect tumor–immune state beyond PD-L1 and guide therapeutic decisions Methods We retrospectively analyzed Tempus platform data . Among 2,177 patients with advanced melanoma and RNA sequencing, 145 received first-line PD-1 monotherapy and 222 CTLA-4/PD-1 combination. LAG3 and CD274 (PD-L1) transcript levels were evaluated as dichotomous variables. Outcomes included objective response rate (ORR) at 90 days and real-world overall survival (rwOS). We assessed treatment–biomarker (LAG3/CD274) interactions and performed statistical de-correlation and fit treatment-specific multivariable Cox models including LAG3 expression, CD274 expression, and estimated CD8 T-cell infiltration . We also explored LAG3 association with immune infiltrate, tumor mutation - and neoantigen-burdens. Results Under monotherapy, high LAG-3 was associated with improved outcomes, ORR (67% vs 15%, p = 0.002); risk of death (HR 0.64; p < 0.001). In contrast, ORR and risk of death were similar for the combination cohort regardless of LAG-3 expression (HR 0.94, p = 0.6). After de-correlation, LAG-3 retained significant association with rwOS under monotherapy, whereas the association for CD274 was attenuated, indicating non-redundant biomarker information. In multivariable Cox analysis including continuous LAG3, CD274, and estimated CD8 T-cell infiltration, LAG3 remained independently associated with improved rwOS in the PD-1 monotherapy cohort (HR 0.54, 95% CI 0.32-0.91; p = 0.021), whereas neither CD274 nor CD8 infiltration remained significant. No biomarker significantly discriminated outcomes within the combination therapy cohort. Conclusions These findings support further validation of LAG3 RNA expression as a candidate biomarker for frontline immunotherapy selection in advanced melanoma.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →